Eli Lilly, Trump and Medicare
Digest more
Trump administration partners with pharma to cut GLP-1 drug prices, impacting out-of-pocket costs for patients.
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results